Lifemd, Inc. · NASDAQ:LFMD
Lifemd — Conversion Labs — Investor Presentation (October 2020)
24 slides from Lifemd's investor presentation, Oct 19, 2020
Slide 1: Conversion Labs October 2020
, CONVERSIONLABS C) qe” October 2020
Slide 2: Important Cautions Regarding Forward-Looking Statements
CONVERSIONLABS OTCQB:CVLB Important Cautions Regarding Forward-Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements relating to future events, and as such all forward-looking statements are made pursuant to the Securities Lit
Slide 3: Conversion Labs is an emerging leader in telehealth
CONVERSIONLABS orcas:cvis Conversion Labs is an emerging leader in telehealth, with a growing portfolio of direct-to-consumer ( )) telemedicine brands. heron Step 5/5 Medical Questionnaire ¢ Brands combine virtual medical treatment with prescription rs . . Get started with line medications and uniqu
Slide 4: The Telemedicine & Online Pharmacy Opportunity is Massive
CONVERSIONLABS OTCQB:CVLB The Telemedicine & Online Pharmacy Opportunity is Massive Conversion Labs has a first-mover advantage in the U.S. telehealth and online pharmacy market and is well positioned to capitalize on this disruption. US virtual care visits to soar to over 1 billion in 2020.” 70% 70
Slide 5: Conversion Labs is Uniquely Positioned to Capitalize on Online Pharmacy and Telemedicine
CONVERSIONLABS OTCQB:CVLB Conversion Labs is Uniquely Positioned to Capitalize on the Growth of Online Pharmacy and Telemedicine Core competency in all aspects of digital marketing and patient acquisition Proprietary, vertically integrated and highly optimized marketing and telehealth technology inf
Slide 6: Major Consumer and Healthcare Trends are Driving the Growth of Telemedicine
CONVERSIONLABS OTCQB:CVLB Major Consumer and Healthcare Trends are Driving the Growth of Telemedicine Healthcare Trends = Costs of healthcare rising due to aging population and poor public policy = Process of seeking medical care usually takes more than two hours? = Physician shortages and overloade
Slide 7: Our End-to-End Telehealth Customer Acquisition Model & Lifecycle
CONVERSIONLABS OTCQB:CVLB Our End-to-End Telehealth Customer Acquisition Model & Lifecycle 1. Acquisition Patient/customer views online ad, visits our website, initiates OTC checkout or Rx screening. 2. Screening Patient/customer completes detailed online medical screening. 3. Scheduling 7. Follow U
Slide 8: Strong Revenue Growth & Financial Performance
CONVERSIONLABS OTCQB:CVLB Strong Revenue Growth & Financial Performance Revenue Growth 220% 80% YoY Est. Revenue Revenue CAGR Growth in 2020 2015-2019 $40.0m+ a $28.5M g J $47M+ 220,000+ E Annualized Net Revenue Cust 1 g Run-Rate & Growing Ustomers § o $12.5M Ee ia 3M 3 $5.2M 1 - - - $0.7™M _$1.2M S
Slide 9: Proven Direct Response Marketing Ability
CONVERSIONLABS OTCQB:CVLB Proven Direct Response Marketing Ability Consistent Top-Line Revenue Growth Since Launch of Core Brands Telemedicine/OTC Brands SaaS Business Unit $10.0M $2.0M $9.0M $1.8M $8.0M $1.6M $7.0M $1.4M $6.0M $1.2M $5.0M $1.0M $4.0M $0.8M $3.0M $0.6M $2.0M $0.4M $1.0M jj [| 1 | $0
Slide 10: Our Business Units
CONVERSIONLABS — OTCQB:CVLB Our Business Units Veritas MD™ 10 1. Veritas MD launch planned for October 2020
Slide 11: Veritas MD
CONVERSIONLABS OTCQB:CVLB Veritas MD™ Designed to be a telehealth platform of the future, Veritas MD was built from the ground up to include all the features required to provide an end-to-end telehealth experience — everything from patient acquisition, consultation and prescribing, to order fulfillm
Slide 12: Rex MD
CONVERSIONLABS OTCQB:CVLB Rex MD Rex MD™ js a digital health clinic for men. Initially focused on erectile dysfunction (ED) treatment, Rex MD will soon offer virtual medical treatment for hairloss, skincare, mental health, primary care, and more. * Launched in December 2019 with virtual treatment fo
Slide 13: Product Line
Product Line oi REX PERFORMANCE WIPES 13
Slide 14: Rex MD Treatment Roadmap
R=X Mi») Treatment Roadmap Qa'20 ar21 a2'21 a3'21 aa'21 ED. PE. Herpes Cold Sores Cold & Flu Hair Loss Allergies dette Testosterone Intra Mody Weight Management = Teledermatology IBs/cD Diabetes Anxiety & Depression ‘Note: Market size based on global spend 1.Grand View Research, 2016 8. Industry Res
Slide 15: Shapiro MD
Shapiro MD Shapiro MD™ is a leading hair loss telemedicine brand for men and women. The brand combines a patented portfolio of OTC hair loss products with virtual medical treatment for hair loss across all 50 states. Developed by distinguished dermatologists Dr. Steven Shapiro, M.D., and Dr. Michael
Slide 16: Product Line
Product Line ) ig a $ ries _ LaserCap — a 16
Slide 17: Shapiro Product Roadmap
SHAPIRO Product Roadmap a4'20 ar'21 221 a3'21 Compounded Topical Rx (Men) Compounding Topical Rx (Women) Eyelash Growth OTC Skincare Teledermatology
Slide 18: SOSRx
CONVERSIONLABS OTCQB:CVLB SOSRx SOSRx™ js a telehealth brand that helps individuals and families prepare for emergency medical situations. The brand’s initial focus is preventative prescription and OTC products for nuclear incidents or terrorism, bioterrorism, flu epidemics, and international travel
Slide 19: PDF Simpli
PDF Simpli PDF Simpli is a SaaS product that enables editing, converting, compressing, splitting, or compressing PDF files. Conversion Labs owns 51% of PDF Simpli through a strategic investment made in June 2018. Scalable search engine marketing (SEM) driven SaaS business model. * PDF market estimat
Slide 20: Key Takeaways
CONVERSIONLABS OTCQB:CVLB Key Takeaways Revenue Growth ° Sales Accelerating: Expecting $40M+ in 2020 vs $12.5M in 2019 ¢ Our telehealth infrastructure build out in 2019, now a major growth driver in 2020 $28.5M e Launched Rex MD, our first telehealth brand, in Q4 2019 ¢ Additional telehealth offerin
Slide 21: Contact Us
CONVERSIONLABS OTCQB:CVLB Contact Us CONVERSIONLABS Company Contact: Investor & Media Contact: Justin Schreiber Ron Both or Grant Stude President & CEO CMA Group justin@conversionlabs.com investors@conversionlabs.com (949) 432-7566 See” CVLB conversionlabs.com
Slide 22: Appendix
CONVERSIONLABS OTCQB:CVLB Appendix
Slide 23: Stock & Operational Highlights
a CONVERSIONLABS OTCQB:CVLB Stock & Operational Highlights Share Structure (As of 10/16/20) Common Shares Issued 16,778,869 Warrants* 1,361,019 Options 3,448,400 Total? 21,588,288 Stock Information Symbol cvLB Share Price* $6.75 52-Week Stock Range $0.55 - $10.70 Average Daily Volume (50 Day)* 670.7
Slide 24: Management | Board | Advisors
Justin Schreiber John R. Strawn, Jr. Anthony G. Bruzzese, M.D. Michael Borenstein, M.D. Joseph V. Ditrolio, M.D. Stefan Galluppi Bertrand Velge Happy Walters CONVERSIONL ABS Management | Board | Advisors greasy Board of Directors Chairman Director Director Director Director Director Director Directo
Conversion Labs — Investor Presentation (October 2020) on 6ix